Genetic variant in a BaP-activated super-enhancer increases prostate cancer risk by promoting AhR-mediated <i>FAM227A</i> expression.

Moreover, the expression of FAM227A showed an increasing trend with an increasing Gleason score ( Supplementary Fig. 6A ); a higher pathologic T or N stage associated with a higher expression level of FAM227A ( Supplementary Fig. 6B and 6C ); and the increased expression of FAM227A was significantly associated with biochemical recurrence ( Supplementary Fig. 6D ).

also in 63,971 other papers